Business Information
The group's principal activities are to design, develop, manufacture and market medical device for the treatment of epilepsy and other debilitating neurological, psychiatric diseases and other disorders. The product of the group is the cyberonics vns therapy system. The vns therapy system delivers an electrical signal through an implantable lead to the left cervical vagus nerve in the patient's neck on a chronic, intermittent basis. It markets its products in the United States, Germany, France, Austria, Switzerland, Belgium, Norway, Sweden, Denmark and the United Kingdom.
|
|
Name |
Title
|
Email
|
| Hugh Morrison | Non - Exec. Chmn. | Available | | Gregory Browne | Pres. - Finance, CFO | Available | | Richard Rudolph | VP - Clinical, Regulatory, Medical Affairs, Chief Medical Officer | Available | | Randal Simpson | VP - Quality, Operations and Research & Development | Available | | Alan Olsen | Dir. | Available
|
|
|
Year |
Sales |
Net Income |
| 2004 | 110,721 | 6,760 | | 2005 | 103,443 | (12,218) | | 2006 | 123,442 | (59,069)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
